View Older Stories View More Recent Stories
-
Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults
-
Moderna (MRNA) PT Lowered to $39 at Bernstein Amid 'Policy Uncertainty'
-
CDC Plans Large Study Into Potential Connections Between Vaccines and Autism - Reuters
-
Moderna (MRNA) call put ratio 1.3 calls to 1 put amid wide price movement
-
Genevant Sciences (ROIV) and Arbutus Biopharma (ABUS) Initiate International Patent Infringement Enforcement Actions Against Moderna
-
Moderna (MRNA) Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine
-
Moderna's Bird Flu Shot Contract Under Review By Trump Admin - Bloomberg
-
Moderna to Present at Upcoming Conferences in March 2025
-
Clorox (CLX) gains 2.7% on new virus concerns
-
Moderna (MRNA) Strength tied to Speculation About New Coronavirus
-
RBC Capital on Moderna (MRNA): 'Next Few Months Key'
-
Barclays Downgrades Moderna (MRNA) to Equalweight
-
Bernstein SocGen Group Reiterates Market Perform Rating on Moderna (MRNA)
-
Moderna (MRNA) PT Lowered to $25 at Wolfe Research
-
Moderna (MRNA) Misses Q4 EPS by 18c; offers guidance
-
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates
-
Moderna faces revenue pressures as analysts cut estimates ahead of earnings
-
RFK, Jr. said confirmed
-
Moderna (MRNA) call put ratio 1.6 calls to 1 put into quarter results
-
Moderna (MRNA) call put ratio 1.4 calls to 1 put into quarter results
-
Moderna (MRNA) on Watch as RFK Jr. Clears Senate Committee, Will Get Full Vote To Head HHS
-
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025
-
Goldman Sachs Downgrades Moderna (MRNA) to Neutral
-
Moderna stock rises following RFK Jr's comments
-
Moderna (MRNA) Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
-
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union
-
Moderna Announces Updates on Pandemic Influenza Program
-
Moderna (MRNA) Awarded $590M for Bird Flu Vaccine Development - Reuters
-
Bernstein Weighs in on US Biopharma Sector in 2025; Highlights LLY as Top-pick
-
Moderna (MRNA) updates 2025 expected revenue range to $1.5 to 2.5 billion
-
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
-
Bernstein SocGen Group Reiterates Market Perform Rating on Moderna (MRNA) as Stock Hikes
-
Moderna (MRNA) call put ratio 5.1 calls to 1 put as share price up 12.5%
-
Moderna (MRNA) CEO Issues Letter to Shareholders
-
Argus Downgrades Moderna (MRNA) to Hold
-
Palantir (PLTR), MicroStrategy (MSTR), and Axon (AXON) to join NASDAQ 100
-
Palantir (PLTR), Microstrategy, Inc. (MSTR) Likely to Join Nasdaq 100 as Moderna (MRNA) Exists - Bloomberg Intelligence
-
Could Moderna stock be due for rally in 2025? Jefferies weighs in
-
Carisma Therapeutics (CARM) plans reduction in the workforce by 34%
-
Leerink Partners Cautious on Moderna (MRNA): 'Tick Tick Tick – Getting More Cautious on CMV as Timelines Drag on'
-
Moderna to Present at Upcoming Conferences in December 2024
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
Berenberg Starts Moderna (MRNA) at Hold
-
Moderna (MRNA) PT Lowered to $69 at Piper Sandler
-
Moderna (MRNA) call put ratio 1 call to 6 puts
-
Moderna (MRNA), Others on Watch Following Report Trump Expected to Select Robert F. Kennedy Jr. to lead HHS
-
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
-
Moderna (MRNA) Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
-
Carisma Therapeutics (CARM) Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma
-
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
